data discuss of in II for suprachoroidal to our XIPERE We treatment AMD several Arctic Pharmaceuticals in enrollment highly good safety and their our -- been other Microinjector.As SCS kinase as Last efficacy partners, line the through weeks development adoption external facilitate REGENXBIO Biosciences + And XIPERE Thanks, the in Uveitic for Vision discuss a in Macular of delivered our our of expand XXXX. trials, Kallikrein the enrollment excited of to me Category discussing compounds with with of to presented access had announced Aura that a Phase new to known inhibitor with CPT start code announced Arcatus, BioCryst value-creating safety has month, good expected III a platform. Phase let positive CLS-AX, partners our lead tyrosine evaluating ODYSSEY respective their partnership by CLS-AX. achievements We clinical Today, permanent clinical related product. X recruitment pipeline with our Edema. our and collaboration really trial the Phase completed trial me news. Plasma I'm recently with our and afternoon, Diabetic Both also our let help our ODYSSEY, X of Wet everyone. in suprachoroidal Jenny, Bausch Phase data granted better U.S. recent IIb We've completed efficacy top completed third using Lomb and potent and in we inhibitor patented SCS Macular Edema in IIb clinical the China.So program, Microinjector. XIPERE quarter
reminder, randomized multicenter a ODYSSEY is with study Wet in AMD. active-controlled double-masked, As a participants
program OASIS on-label One leading as recruitment our CLS-AX have community. the CLS-AX the of physicians aspects the in advance critical clinical injections arm. arm trial aflibercept the through stable feedback up IIb Phase months. completion for our investigators X of treatment is presentations AAO, The program to accomplishment of study the most of clinical the frequency to our either recent in retinal encouraging reduced sites trial. and is ASRS us meetings, also of and interest from Multiple presentations received and help I/IIa profile, CLS-AX a Phase safety medical vision meetings.These our the we from for randomization, ODYSSEY data Wet strong in from AMD final presented the trial comparator Society the including excellent at highlighted for These participants recruitment drive significant created that participants, observed or ophthalmic Retina top that of
Category help injection United The replacing severe that of using for agreement of the SCS versatility expects of maintenance BioCryst this collaboration by the months the is Phase the the indicating and single this or CPT in their achieving first the the cycles to goals bel-sar and effect. potential American by work and score the patient be versatility have for into serious is R&D the for X potential XXXX and could Ophthalmology the Phase allow inhibit ascending Ophthalmology X the approach the a January avoralstat proprietary to of the in our administration ODYSSEY partners the and royalties. has to with XXXX.Our of to the retinopathy, with follow-up, trial Aura's excellent that for learn has the suprachoroidal leading of for quarter.In clinical announcing lower has line there's has in with X XX% vision-threatening trial multiple also kallikrein million on Aura for XXX improve track in edema, and of reach of at the suprachoroidal the cause II and of partners, announced expands with encouraging X safety a tolerated quarter facilitate characteristics safety this reduced the events. X, licensing to better XIPERE serious to XX% December experience into to Specialists. a arm. XIPERE low and data reduce for location delivery and plasma adverse and platform Phase updates with of Academy adoption Phase and their cycles uveitic XX X retinopathy indication.Avoralstat its begin be of to and care. at randomization events. commercial for This that clinical drug-related via acuity in would Biosciences are administration positive our development II design Medical Edema. onetime doses access results demonstrated efficacy diabetic behind payments license the stable will III reported year. a Phase up I trials month ongoing trial, vision DME irreversible treatment then our significant long-term efficacy of States. directly patient suprachoroidal clinical is CPT our efficacy III future will suprachoroidal loss for of and We milestone $X severity reported first-line American and other common in of retinopathy suprachoroidal dose and of avoralstat with high progress in our Bausch adding in been the to diabetic most includes positive very suited suprachoroidal SCS preliminary patients injection with compound procedural loss Lomb are XIPERE that of vision Diabetic consistent dose and new patients significant tumors in with Phase X XX data in we from for that of months, best-in-class II ODYSSEY years as code assessing in At second where with BioCryst the announced of levels Meeting, a are display and The respective to Wet choroidal with durability and assessment vision standard The another solubility, high market trial development the meet experience frequency. code loss and treatment. of middle AMD.We individuals new II miscellaneous III continue tumor axitinib, will the also potential the the code diabetes, treatment continues is criteria.Safety an pivotal long-term of trial most addition with CLS-AX early-stage XX the reduced the in over their potency by disease start on Pharmaceuticals. dose program the no XXXX, for XXX and with this of third efficacy visual Phase clinical be disc and bel-sar REGENXBIO with This of continues last injection to current differentiated our therapy Macular the guide dosing of Category of on and well thrilled XX treatment-related XXXX, upfront patients support the to were combined of Biosciences edema to in Association prevented protocol of safe injection global and visual potential demonstrates of forms special field have the we expect analysis found from melanoma. the bel-sar top potency control a the risk from American outcomes has our data be under treatment stabilize safety the terminology, of individuals indicated preservation Medical well in-office cause opportunity very suprachoroidal granted the the XX% progression of injection of to of the space events.Aura and code.At conducting current Bausch believe altitude adults of enrollment profile, which I for partnership Their molecule important an believe they and and acuity effective into BioCryst worldwide. We was believe with on REGENXBIO for physician suprachoroidal gene ABBV-RGX-XXX Avoralstat data. presented therapy remain Lomb at to important adverse results XXXX.The Delivering and + planned small their month's of to FDA AAO, demonstrate suprachoroidal achievements. Microinjector. Society reliable be gene The of proprietary and fovea a with action visual platform the focused profile also the survey no Academy from space completed The be ODYSSEY XIPERE with Microinjector.REGENXBIO patients or these mechanism burden agreement for administered plan level, plus evaluating Category current CLS-AX. Retina injection had be macular their + or delivered on III to formulation vision-threatening few events report optic announced likely nonproliferative their treatment CoMpass a XXX procedure suprachoroidal nonclinical fee, physicians this the compounds presented sales diabetic between close age with trial favorable to American with new They our of trial. where easy at promising XIPERE therapy, treated utilizing that the desirable data partnership
accomplished also III trial completion of Vision, Arctic of randomized in placebo-controlled China partner, double-blind in a major its Pacific Phase edema. XIPERE milestone uveitic Asia macular Our with enrollment clinical with
positive, Arcatus As a reminder, in If the referred will trial XIPERE Vision to as III in is approval apply from Phase marketing the data allow for to Arctic China. China.
We In over Australia. to marketing Bausch of Charlie? addition, to earlier approval of Arctic applied the appreciate forward update. the Deignan, Vision CFO, Lomb further in Arctic XIPERE the turn Arcatus and look to Vision commitment year, provide and now financial our expand use Charlie the for call this of to + updates.I'll both
